Literature DB >> 14665613

Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.

Stergios J Moschos, John M Kirkwood, Panagiotis A Konstantinopoulos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14665613     DOI： 10.1200/JCO.2004.10.952

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4⁺ and CD8⁺ T cells.

Authors:  Kristan D Guenterberg; Gregory B Lesinski; Bethany L Mundy-Bosse; Volodymyr I Karpa; Alena Cristina Jaime-Ramirez; Lai Wei; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2011-05-21       Impact factor: 6.968

2.  [Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma].

Authors:  E Richtig; G Langmann; G Schlemmer; K Müllner; G Papaefthymiou; P Bergthaler; J Smolle
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

Review 3.  Melanoma in pediatric, adolescent, and young adult patients.

Authors:  John M Kirkwood; Drazen M Jukic; Bruce J Averbook; Leonard S Sender
Journal:  Semin Oncol       Date:  2009-10       Impact factor: 4.929
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.